![]()
|
|
||||||||
J. Biol. Chem., Vol. 282, Issue 2, 1010-1017, January 12, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





¶**
||**1
From the
Inflammation Program, Department of Internal Medicine, ¶Department of Microbiology, ||Department of Biochemistry, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, **Veterans Affairs Medical Center, Iowa City, Iowa 52246, and
Department of Molecular Sciences, University of Tennessee Health Science Center, Memphis, Tennessee 38163
Received for publication, October 4, 2006
| ABSTRACT |
|---|
|
|
|---|
190,000 complex composed of endotoxin, MD-2, and TLR4ECD. CD14 facilitates transfer of endotoxin to MD-2 (TLR4) but is not a stable component of the endotoxin·MD-2/TLR4 complex. The ability to assay specific high affinity interactions of monomeric endotoxin·protein complexes with TLR4ECD should allow better definition of the structural requirements for endotoxin-induced TLR4 activation. | INTRODUCTION |
|---|
|
|
|---|
106 endotoxin molecules) to 106 TLR4-activating monomeric endotoxin·protein complexes (i.e. endotoxin·CD14 or endotoxin·MD-2), greatly amplifying host responsiveness to endotoxin. At pM concentrations, monomeric complexes of endotoxin·CD14 or endotoxin·MD-2 activate, respectively, mammalian cells expressing MD-2/TLR4 or TLR4 alone, triggering robust cell activation through engagement of <103 TLR4 molecules.
Despite the ability of endotoxin·CD14 and endotoxin· MD-2 to activate cells at pM concentrations (half-maximal cell activation is <50 pM), published estimates of TLR4-dependent cellular interactions of endotoxin have indicated an apparent Kd of
3 nM (1015). It is possible that brief occupation of a small subset of TLR4 is sufficient for robust cell activation. However, an important limitation of earlier studies has been the likelihood that much of the endotoxin added was not presented as the monomeric protein·endotoxin complex that is likely the preferred substrate for MD-2/TLR4 or TLR4 alone. In contrast to the remarkable progress in identification and characterization of the intracellular biochemical machinery responsible for TLR signaling, there is still virtually nothing known about the specificities of ligand-receptor interaction for any of the TLRs. In nearly all cases, TLR recognition has been inferred from the measurement of receptor activation, not binding, properties of specific compounds.
In this study, we have made use of our ability to produce and isolate stable endotoxin·protein complexes of high specific radioactivity (
25,000 cpm/pmol) to more rigorously and directly characterize ligand-receptor interactions involving endotoxin and TLR4. For this purpose, we have expressed, in HEK293T cells, the predicted ectodomain of human TLR4 (amino acids 24634, TLR4ECD) (16) with or without human MD-2 to permit direct assay of endotoxin interactions with TLR4ECD ± MD-2. We describe, for the first time, the direct binding of endotoxin·MD-2 complex to the predicted TLR4 ectodomain in the absence of any other cellular or extracellular co-factors and the direct transfer of endotoxin from CD14 to MD-2/TLR4ECD. These interactions are highly specific and of very high affinity (Kd
300 pM) and fully consistent with the molecular requirements for potent mammalian cell activation by endotoxin. Both binding of endotoxin·MD-2 to TLR4ECD and transfer of endotoxin from endotoxin·CD14 to MD-2/TLR4ECD result in the formation of a stable complex that is composed of endotoxin, MD-2, and TLR4ECD without CD14.
| EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Production of Recombinant ProteinHEK293T cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Cells (
80% confluency in T75 flasks) were transfected with 12 µg of DNA using PolyFect reagent (Qiagen). After 12 h, plates were rinsed in PBS and 8 ml of serum-free medium (293 SFM, Invitrogen) ± [3H]LOS·sCD14 (1 nM; see below) were added. Medium containing expressed proteins was collected 2448 h later. Medium was concentrated 1020-fold using Millipore Centricon-10 before use. Conditioned medium containing secreted TLR4ECD and MD-2/TLR4ECD proteins maintained activity to react with [3H]LOS·MD-2 or [3H]LOS·sCD14 for at least 6 months when stored at 4 °C. Expression vectors containing the DNA of interest for production of FLAG-TLR4ECD, amino acids 24634, (pFLAG-CMV-TLR4) and MD-2-FLAG-His (pEF-BOS) have been previously described and characterized (16).
cDNA encoding MD-2 and sCD14-(1156) were inserted (17) into pBAC11 (Novagen) using XhoI and NotI-sensitive restriction sites. This provides a 5'-flanking signal sequence (gp64) to promote secretion of protein and a C-terminal six-residue polyhistidine tag. Sf9 cells were used for transfection and amplification of baculovirus, whereas High Five cells in serum-free medium were used for protein production (17). Conditioned medium containing secreted MD-2-His6 was used directly for generation of LOS·MD-2. Conditioned medium containing sCD14-(1156)-His6 was dialyzed against 20 mM phosphate, 0.5 M NaCl, adsorbed to Ni2+ FF-Sepharose equilibrated in the same buffer, washed, and the adsorbed protein eluted by an imidazole gradient (Explorer 100 fast protein liquid chromatography, GE Healthcare).
Preparation of [3H]LOS·Protein Complexes[3H]LOSagg, [3H]LOS·sCD14, and [3H]LOS·MD-2 complexes were prepared as previously described (8, 17, 19). Briefly, [3H]LOSagg (Mr > 20 x 106) was obtained after hot phenol extraction of [3H]LOS followed by ethanol precipitation of [3H]LOSagg and ultracentrifugation. Monomeric [3H]LOS·CD14 complexes (Mr
60,000) were prepared by treatment of [3H]LOSagg for 30 min at 37 °C with substoichiometric LBP (molar ratio 200:1 of LOS:LBP) and equimolar sCD14 followed by gel exclusion chromatography (Sephacryl S200, 1.6 x 70-cm column) in PBS, pH 7.4, 0.03% HSA to isolate monomeric [3H]LOS·sCD14 complex. [3H]LOS·MD-2 (Mr
25,000) was generated by treatment of [3H]LOS·sCD14 (30 min at 37 °C) with High Five insect cell medium containing MD-2-His6 followed by isolation of [3H]LOS·MD-2 by S200 chromatography.
Tetraacylated LOS (specific activity
16,000 cpm/pmol) was prepared by partial deacylation of [3H]LOS with AOAH according to the method of Munford and Erwin (20), and [3H]LOSAOAH·MD-2 was prepared and isolated as described previously (21). The extent of deacylation of [3H]LOS by AOAH was monitored by separation of released [3H]-free fatty acids from partially deacylated and remaining intact [3H]LOS by ethanol precipitation. Ethanol-soluble radioactivity representing released [3H]fatty acids was analyzed by liquid scintillation spectroscopy (20, 21);
90% [3H]LOS was deacylated (21). Radiochemical purity of [3H]LOSagg, [3H]LOS·sCD14, and [3H]LOS·MD-2 was confirmed by Sephacryl S500 (LOSagg) or S200 ([3H]LOS·sCD14, [3H]LOS·MD-2) chromatography (17, 18).
Reaction of Secreted TLR4ECD and MD-2/TLR4ECD with [3H]LOS·Protein Complexes[3H]LOSagg, [3H]LOS·sCD14, or [3H]LOS·MD-2 (1 nM or as indicated) was incubated with concentrated (810x) conditioned medium ± proteins diluted to a final volume of 0.5 or 1 ml in PBS, pH 7.4, for 30 min at 37°C. In most experiments, conditioned medium harvested after a 48-h culture of transfected HEK293T cells in serum-free medium was used for incubations with [3H]LOSagg, [3H]LOS·sCD14, or [3H]LOS·MD-2. However, in selected experiments, the serum-free medium was spiked with [3H]LOS·sCD14 (1 nM) at the time of the addition of medium to the transfected cells to permit reaction of MD-2 with [3H]LOS·sCD14 upon secretion. Medium harvested without [3H]LOS·sCD14 is expressed (see Figs. 1 and 2, 3, 4, 5) as recombinant protein secreted in cm, whereas medium spiked with [3H]LOS·sCD14 during cell culture are represented as HEK/recombinant protein(s) secreted + [3H]LOS·sCD14 (see Fig. 4). Reaction products were analyzed by Sephacryl HR S200 or S300 (1.6 x 70 cm) chromatography in PBS, pH 7.4, ±0.5 mM Mg2+, 1 mM Ca2+, 0.03% HSA. Divalent cations and HSA were used in columns with LOSagg to improve recoveries of LOSagg. Fractions (0.5 ml) were collected at a flow rate of 0.3 ml/min at room temperature using AKTA Purifier or Explorer 100 fast protein liquid chromatography (GE Healthcare). Radioactivity in collected fractions was analyzed by liquid scintillation spectroscopy (Beckman LS liquid scintillation counter). Recoveries of [3H]LOS were
70% in all cases. All solutions used were pyrogen-free and sterile-filtered. After chromatography, selected fractions were sterile-filtered (0.22 µm) and kept at 4 °C for 36 months with no detectable changes in chromatographic or functional properties. The same conditioned medium was used for all concentrations of [3H]LOS·sCD14 or [3H]LOS·MD-2 used for Scatchard analysis. Multiple preparations of conditioned medium contained similar amounts of TLR4ECD or MD-2/TLR4ECD, i.e. 12 and 34 pmol/ml, respectively.
Characterization of [3H]LOS-containing Complex
Determination of Apparent SizeSephacryl S300 used for determination of apparent Mr was calibrated with the following proteins: blue dextran (2 x 106, V0), thyroglobulin (650,000), ferritin (440,000), catalase (232,000), IgG (158,000), HSA (66,000), ovalbumin (44,500), myoglobin (17,500), vitamin B12 (1200, Vi). For size determination, the complex containing [3H]LOS was resolved in the presence of at least three protein standards. Protein standards were detected by A280 and the [3H]LOS-containing complex by liquid scintillation spectroscopy. Mr was calculated using GraphPad Prism version 4.
Co-capture AnalysesThe protein composition of [3H]LOS-containing complexes generated from incubation of [3H]LOS·MD-2-His6 with medium containing FLAG-TLR4ECD or of [3H]LOS·sCD14 with medium containing MD-2-FLAG-His6 and FLAG-TLR4ECD was determined by monitoring [3H]LOS adsorption to resins that specifically interacted with either TLR4 or MD-2. Co-capture of [3H]LOS associated with MD-2-FLAG-His6 (HEK293T cell-derived) or MD-2-His6 (insect cell-derived) was performed using Ni2+ FF-Sepharose resin pre-equilibrated in either PBS (product containing MD-2-FLAG-His6) or 20 mM phosphate and 0.5 M NaCl, pH 7.4, (product containing MD-2-His6). Resin (
50 µl) was incubated with 0.2 pmol [3H]LOS-containing complexes for 1 h at room temperature. The resin was spun down, supernatant was removed, and the resin was washed with PBS, pH 7.4, or 20 mM phosphate, 0.5 M NaCl, pH 7.4, before elution with 2% SDS or 0.5 M imidazole. [3H]LOS absorbed to the resin was evaluated by liquid scintillation spectroscopy.
Detection of FLAG-TLR4ECD in [3H]LOS-containing complexes was determined by adsorption to anti-FLAG-agarose (for the product of the reaction of [3H]LOS·MD-2-His6 + (FLAG-TLR4ECD)cm) or by reaction with biotinylated HTA125 anti-TLR4 antibody followed by adsorption to streptavidin-agarose (for the product of the reaction of [3H]LOS·sCD14 with (MD-2-FLAG-His6/FLAG-TLR4)cm). [3H]LOS-containing complex (0.2 pmol) was incubated with 75 µl of anti-FLAG-agarose in 0.5 ml of buffer (PBS, pH 7.4, or 20 mM phosphate and 0.5 M NaCl, pH 7.4) overnight at 4 °C on a rotating wheel. The supernatant was collected after spinning (2000 revolutions/min, 5 min, 4 °C), and the sedimented beads were washed three times with 20 mM phosphate and 0.5 M NaCl before [3H]LOS adsorbed to beads was determined by liquid scintillation spectroscopy. Immunocapture by anti-TLR4 antibody of [3H]LOS-containing complex (0.2 pmol) was performed by incubation of the complex with 2 µg of biotinylated HTA125 anti-TLR4 antibody (or non-biotinylated HTA125 as a negative control) in PBS, pH 7.4. After overnight incubation at 4 °C with the sample, 50 µl of PBS-equilibrated streptavidin-coupled agarose beads were added for an additional 1 h at room temperature. Adsorbed [3H]LOS-containing complex was determined by measuring [3H]LOS associated with the washed agarose.
| RESULTS |
|---|
|
|
|---|
To circumvent these limitations and permit more direct assay of the molecular requirements for endotoxin-TLR4 interactions, we transiently expressed, in HEK293T cells, an N-terminal fragment of recombinant human TLR4 (residues 24634) corresponding to the predicted ectodomain of TLR4 (TLR4ECD) and containing an N-terminal FLAG tag. Harvested control and TLR4ECD-containing culture media were incubated with 1 nM of purified [3H]LOS aggregates (LOSagg), monomeric [3H]LOS·sCD14, or [3H]LOS·MD-2-His6. Interaction of the various forms of [3H]LOS with TLR4ECD was monitored by gel filtration analysis to assay for TLR4ECD-dependent changes in the physical state of [3H]LOS. Under these experimental conditions, only [3H]LOS·MD-2 reacted with TLR4ECD (Fig. 1). Incubation of [3H]LOS·MD-2 with conditioned medium containing TLR4ECD (but not control medium) yielded a novel [3H]LOS-containing product (Fig. 1A, encircled peak) whose formation depended upon TLR4ECD and the presentation of [3H]LOS as [3H]LOS·MD-2 (Fig. 1, compare A to B and C). Neither [3H]LOSagg nor [3H]LOS·sCD14 showed interaction with TLR4ECD (Fig. 1, B and C), even when added at 200x greater LOS concentrations (data not shown). These findings strongly suggest a specific and direct interaction of [3H]LOS·MD-2 with TLR4ECD.
Rechromatography on Sephacryl S300 of the newly formed [3H]LOS-containing product recovered after incubation of [3H]LOS·MD-2-His6 with medium containing FLAG-TLR4ECD (Fig. 1A, encircled fractions) yielded a single symmetrical peak that, by comparison to elution of protein standards, gave a predicted Mr
190,000 (Fig. 1D). [3H]LOS in the product could be captured by anti-FLAG (Fig. 1F) antibodies as well as by Ni+2-chelating resin (Fig. 1E), indicating the presence of MD-2-His6 as well as [3H]LOS and FLAG-TLR4ECD in the Mr
190,000 complex.
The high specific radioactivity of [3H]LOS·MD-2 permitted quantitative assay of the formation of the Mr
190,000 complex at pM concentrations of [3H]LOS·MD-2 and under conditions where the concentration of TLR4ECD was limiting. Formation of the Mr
190,000 complex was dependent on [3H]LOS·MD-2 concentration and saturated at
1 nM [3H]LOS·MD-2 with half-maximal formation at
200300 pM [3H]LOS·MD-2 (Fig. 1H). Equilibrium conditions were met after 30 min at 37 °C as equal amounts of product were formed at 30 and 120 min. Scatchard analysis (Fig. 1H) indicated an apparent KD of
300 pM for the reaction of [3H]LOS·MD-2 with TLR4ECD. The interaction of [3H]LOS·MD-2 (25,000 cpm/pmol) with TLR4ECD could be competed with weakly labeled [14C]LOS·MD-2 (625 cpm/pmol) but not [14C]LOSagg or LOS·sCD14 (data not shown), further demonstrating the specificity of the interaction of LOS·MD-2 with TLR4ECD.
|
190,000 complex increased with increasing concentrations of [3H]LOS·sCD14 (Fig. 2G) and was saturable with an apparent KD of
130 pM (Fig. 2H).
Production of apparently the same Mr 190,000 complex from incubation of [3H]LOS·sCD14 with culture medium containing TLR4ECD and MD-2 as that resulting from the reaction of TLR4ECD-containing medium with [3H]LOS·MD-2 strongly suggested that [3H]LOS·sCD14 transferred [3H]LOS to a complex containing MD-2 and TLR4ECD without CD14 becoming part of this newly formed complex. To test that hypothesis, we took advantage of the fact that the ability of CD14 to bind endotoxin and transfer endotoxin to MD-2 requires only the N-terminal 152 amino acids of CD14 (full-length CD14 is 356 residues) (2326). [3H]LOS·sCD14 (full-length) and [3H]LOS·sCD14-(1156) were readily resolved by gel-sieving chromatography (Fig. 3). However, incubation of conditioned medium containing MD-2/TLR4ECD with either [3H]LOS·sCD14 or [3H]LOS·sCD14-(1156) yielded the same Mr
190,000 complex (Fig. 3). That the product formed by reaction of 1) [3H]LOS·MD-2 + TLR4ECD, 2) [3H]LOS·sCD14 + MD-2/TLR4ECD, and 3) [3H]LOS·sCD14-(1156) + SMD-2/TLR4ECD is apparently the same size strongly suggests that CD14 is neither a component of nor necessary for the formation of the Mr
190,000 complex.
|
|
25,000) despite the secretion of more MD-2 than TLR4ECD (data not shown). We speculated that this reflected the instability of secreted MD-2 in serum-free culture medium at 37 °C, as previously reported by Kennedy et al. (15). To test this hypothesis, we compared the products generated when [3H]LOS·sCD14 was incubated with culture medium harvested after transfection (as in Fig. 2A) or was spiked into the culture medium 12 h after transfection so that, immediately upon secretion, MD-2 could potentially react with [3H]LOS·sCD14. [3H]LOS·MD-2 was generated in significant amounts only when [3H]LOS· sCD14 was present during secretion of MD-2. This was seen whether or not TLR4ECD was also expressed (compare Fig. 4A with Figs. 2A and 3; Fig. 4, compare B with D). In contrast, formation of the Mr
190,000 complex occurred efficiently when [3H]LOS·sCD14 was added either during or after culturing. These findings suggest strongly that, in contrast to free MD-2, the endotoxin binding activity (i.e. reactivity with LOS·sCD14) of MD-2 is stable in serum-free medium at 37 °C when co-expressed/associated with TLR4ECD.
Hexaacylated and Tetraacylated LOS·MD-2 Complexes Show Similar Reactivity with TLR4ECDWe and others (21, 27) have previously shown that differences in TLR4 agonist activity of underacylated versus hexaacylated endotoxin species reflect differences in structural and functional properties of monomeric endotoxin·MD-2 complexes. The ability of underacylated endotoxin·MD-2 complexes to inhibit cell activation by hexaacylated endotoxin·MD-2 suggested that, even though underacylated endotoxin·MD-2 complexes do not efficiently trigger receptor activation, these complexes bind to the TLR4ECD with an affinity comparable with that of hexaacylated endotoxin·MD-2. To test this hypothesis more directly, aggregates of hexaacylated LOS were treated with the deacylating enzyme acyloxyacyl hydrolase (AOAH) and used to generate monomeric complexes with MD-2 ([3H]LOSAOAH·MD-2) containing mainly (
90%) tetraacylated LOS, as has been described previously (21). Incubation of a low concentration (0.6 nM) of [3H]LOSAOAH·MD-2 with medium containing secreted TLR4ECD followed by gel filtration of the products revealed a pattern similar to that seen with the hexaacylated [3H]LOS·MD-2 complex, i.e. formation of the Mr
190,000 complex (Fig. 5), directly demonstrating the similar reactivity of hexa- and tetraacylated LOS·MD-2 complexes with TLR4ECD.
|
|
| DISCUSSION |
|---|
|
|
|---|
nM) activate cells expressing TLR4/MD-2 without CD14 remains to be determined (30). The reactivity of LOS·sCD14 with culture medium containing TLR4ECD and MD-2 (but not TLR4ECD alone) (Fig. 1B) is consistent with an essential role of MD-2 in ligand (endotoxin·CD14) recognition by the MD-2/TLR4 receptor complex. Reaction of LOS·sCD14 with free MD-2 was not detected in culture medium harvested after 48 h of incubation, indicating that the reactant with LOS·sCD14 is preassociated MD-2/TLR4ECD and that, as previously observed, free MD-2 is unstable. The reactivity of LOS·MD-2 with TLR4ECD when TLR4ECD was expressed alone (but not when TLR4ECD was co-expressed with MD-2) also implies that, in the latter situation, TLR4ECD is preoccupied with co-expressed MD-2. The low reactivity of LOS·MD-2 with preformed MD-2/TLR4ECD also indicates that LOS is not readily transferred from LOS·MD-2 to MD-2/TLR4 and that MD-2 associated with TLR4ECD is not readily exchanged with LOS·MD-2.
Previous studies have emphasized the importance of MD-2 in the maturation and surface expression of TLR4 (14, 29, 31, 32). Our findings have revealed a role for TLR4ECD in stabilizing MD-2, perhaps by stabilizing an otherwise labile monomeric form of MD-2 that may be needed for reactivity with endotoxin·CD14 as well as binding to TLR4 (13, 16).3 The apparent stability of MD-2/TLR4ECD is consistent with the functional activity of this heterodimeric receptor, even when low levels of TLR4 and MD-2 are expressed. Although our studies do not directly reveal to what protein endotoxin is bound in the Mr
190,000 complex containing MD-2 and TLR4ECD, the ability of endotoxin·CD14 to react avidly with MD-2 (but not to TLR4ECD) suggests strongly that the primary reaction of endotoxin·CD14 is with MD-2 (±TLR4).
Many investigators have speculated that the reaction of endotoxin·CD14 with MD-2/TLR4 results in engagement of CD14 as an essential component of an activated oligomeric MD-2/TLR4-containing receptor complex (1, 3336). However, the ability of purified endotoxin·MD-2 complex to induce robust (MyD88-dependent) signaling in cells expressing TLR4 without MD-2 (or mCD14) (22) has suggested to us that CD14 is not an obligatory component of a TLR4 receptor complex activated by endotoxin. Our findings that reaction of LOS·sCD14 with MD-2/TLR4ECD yields a product that contains LOS, MD-2, and TLR4ECD (but not CD14 (Fig. 3)) plus the formation of an apparently identical product by reaction of LOS·MD-2 with TLR4ECD (compare Figs. 1 and 2) are consistent with the view that the primary role of CD14 is transfer of endotoxin to MD-2 (±TLR4). However, the requirement of mCD14 for MyD88-independent signaling after endotoxin-induced TLR4 activation suggests a more complex role of CD14 in endotoxin-driven TLR4 activation (1, 30, 37). Our experiments in solution with CD14 and TLR4ECD do not preclude the possibility of more stable endotoxin-induced interactions of mCD14 with activated receptor complexes containing full-length transmembrane TLR4.
Both reaction of monomeric LOS·sCD14 with MD-2/TLR4ECD and of monomeric LOS·MD-2 with TLR4ECD produced a higher order complex of apparent Mr of
190,000 containing LOS, MD-2, and TLR4ECD (Figs. 1 and 2). This nearly matches the predicted Mr of a dimer of a 1:1:1 complex of LOS·MD-2/TLR4ECD (Mr of LOS
5,000, of MD-2
20,000, of TLR4ECD
75,000). Confirmation of this predicted stoichiometry will require preparative purification of Mr
190,000 complex and chemical and immunochemical analyses. It is not yet clear whether this product reflects endotoxin-induced TLR4 dimerization or reaction of monomeric protein·endotoxin complexes with pre-existing TLR4ECD (MD-2) dimers in the harvested culture medium. In either case, the co-capture results shown in Fig. 1 are intriguing. The relatively efficient capture of the Mr
190,000 complex by an activated Ni2+-chelating resin, despite inefficient capture of the LOS·MD-2-His6 (or LOS·MD-2-FLAG-His6; data not shown) complex suggests that the His tag is shielded in the LOS·MD-2 complex from interaction with Ni2+ resin but becomes more accessible upon interaction with TLR4ECD and formation of the Mr
190,000 complex. This suggests a conformational change of MD-2 or of LOS bound to MD-2 upon binding of LOS·MD-2 to TLR4ECD.
In summary, we have demonstrated for the first time pM interactions of endotoxin with TLR4ECD. We have succeeded in demonstrating such high affinity interactions because of our use of purified endotoxin·protein complexes that are the preferred substrate(s) for (MD-2) TLR4ECD and that are in radiolabeled form of very high specific radioactivity, making it possible to detect and quantify intermolecular interactions at pM endotoxin concentrations. The reagents and assays described in this study should now make it possible to define the structural requirements of endotoxin and MD-2 interactions with TLR4ECD in a way that has not been possible before. Our findings are consistent with earlier speculations that the monomeric endotoxin·MD-2 complex, not endotoxin itself, is the ligand for TLR4 (13, 17). As such, the molecular basis of ligand recognition and receptor activation by mammalian TLR4 may resemble more closely that of Drosophila Toll (38) than has been appreciated before. Whether or not, in comparison to other mammalian TLRs, TLR4 is idiosyncratic or instructive of the molecular basis of ligand recognition by other mammalian TLRs (39) remains to be determined.
| FOOTNOTES |
|---|
1 To whom correspondence should be addressed: Roy J. and Lucille A. Carver College of Medicine, University of Iowa and Veterans Affairs Medical Ctr., Inflammation Program, 2501 Crosspark Rd., Coralville, IA 52241. Tel.: 319-335-4253; Fax: 319-335-4191; E-mail: theresa-gioannini{at}uiowa.edu.
2 The abbreviations used are: TLR, Toll-like receptor; TLR4ECD, Toll-like receptor 4 ectodomain; AOAH, acyloxyacyl hydrolase; GNB, Gram-negative bacteria; HEK, human embryonic kidney; HSA, human serum albumin; LBP, lipopolysaccharide-binding protein; LOS, lipooligosaccharide; LOSagg, LOS aggregate; PBS, phosphate-buffered saline; sCD14, soluble CD14; cpm, counts/min. ![]()
3 R. Widstrom, Taghanemt, A., Prohinar, P., Gioannini, T. L., and Weiss, J. P., unpublished observations. ![]()
| ACKNOWLEDGMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Teghanemt, R. L. Widstrom, T. L. Gioannini, and J. P. Weiss Isolation of Monomeric and Dimeric Secreted MD-2: ENDOTOXIN{middle dot}sCD14 AND TOLL-LIKE RECEPTOR 4 ECTODOMAIN SELECTIVELY REACT WITH THE MONOMERIC FORM OF SECRETED MD-2 J. Biol. Chem., August 8, 2008; 283(32): 21881 - 21889. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hadina, J. P. Weiss, P. B. McCray Jr., K. Kulhankova, and P. S. Thorne MD-2-Dependent Pulmonary Immune Responses to Inhaled Lipooligosaccharides: Effect of Acylation State Am. J. Respir. Cell Mol. Biol., June 1, 2008; 38(6): 647 - 654. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Vasl, P. Prohinar, T. L. Gioannini, J. P. Weiss, and R. Jerala Functional Activity of MD-2 Polymorphic Variant Is Significantly Different in Soluble and TLR4-Bound Forms: Decreased Endotoxin Binding by G56R MD-2 and Its Rescue by TLR4 Ectodomain J. Immunol., May 1, 2008; 180(9): 6107 - 6115. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Jain, A. Halle, K. A. Halmen, E. Lien, M. Charrel-Dennis, S. Ram, D. T. Golenbock, and A. Visintin Phagocytosis and intracellular killing of MD-2 opsonized Gram-negative bacteria depend on TLR4 signaling Blood, May 1, 2008; 111(9): 4637 - 4645. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Teghanemt, F. Re, P. Prohinar, R. Widstrom, T. L. Gioannini, and J. P. Weiss Novel Roles in Human MD-2 of Phenylalanines 121 and 126 and Tyrosine 131 in Activation of Toll-like Receptor 4 by Endotoxin J. Biol. Chem., January 18, 2008; 283(3): 1257 - 1266. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Teghanemt, P. Prohinar, T. L. Gioannini, and J. P. Weiss Transfer of Monomeric Endotoxin from MD-2 to CD14: CHARACTERIZATION AND FUNCTIONAL CONSEQUENCES J. Biol. Chem., December 14, 2007; 282(50): 36250 - 36256. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Schultz, J. Hume, D. S. Zhang, T. L. Gioannini, and J. P. Weiss A Novel Role for the Bactericidal/Permeability Increasing Protein in Interactions of Gram-Negative Bacterial Outer Membrane Blebs with Dendritic Cells J. Immunol., August 15, 2007; 179(4): 2477 - 2484. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Gioannini, A. Teghanemt, D. Zhang, P. Prohinar, E. N. Levis, R. S. Munford, and J. P. Weiss Endotoxin-binding Proteins Modulate the Susceptibility of Bacterial Endotoxin to Deacylation by Acyloxyacyl Hydrolase J. Biol. Chem., March 16, 2007; 282(11): 7877 - 7884. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||